Yasushi Kondo1,2, Takashi Fukuyama3, Rui Yamamura4, Nobue Futawatari5, Yoshinobu Ichiki6, Yoichi Tanaka7, Yatsushi Nishi2, Yoshihito Takahashi1,2, Hitoshi Yamazaki8, Noritada Kobayashi4, Masahiko Watanabe1. 1. Department of Surgery, School of Medicine, Kitasato University, Sagamihara, Japan. 2. Division of Surgery, Kitasato University Medical Center, Kitamoto, Japan. 3. Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan fukuyam@insti.kitasato-u.ac.jp. 4. Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan. 5. Department of Surgery Ohashi Medical Center, Toho University, Tokyo, Japan. 6. Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan. 7. Department of Clinical Pharmacy, School of Pharmacy, Kitasato University, Tokyo, Japan. 8. Division of Pathology, Kitasato University Medical Center, Kitamoto, Japan.
Abstract
BACKGROUND: Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a cancer/testis antigen and predominant target for cancer immunotherapy. Its detection is only established based on gene expression. In this study, we established a monoclonal antibody against KK-LC-1 to detect its protein expression in formalin-fixed samples. MATERIALS AND METHODS: The monoclonal antibody against KK-LC-1 was evaluated and the detection of KK-LC-1 between gene expression and protein expression was compared in patients with breast cancer. The monoclonal antibody clone 34B3, which we established, stained testicular germ cells positively. RESULTS: The rates of detection of KK-LC-1 gene and protein expression were 11.8% and 52.9%, respectively. Protein expression was detected in all triple-negative breast cancer cases studied (n=8). Furthermore, KK-LC-1 was detected in all tumours without oestrogen receptor expression. CONCLUSION: This study indicated that KK-LC-1 expression was detected in breast cancer, especially in oestrogen receptor-negative subtypes. Copyright
BACKGROUND:Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a cancer/testis antigen and predominant target for cancer immunotherapy. Its detection is only established based on gene expression. In this study, we established a monoclonal antibody against KK-LC-1 to detect its protein expression in formalin-fixed samples. MATERIALS AND METHODS: The monoclonal antibody against KK-LC-1 was evaluated and the detection of KK-LC-1 between gene expression and protein expression was compared in patients with breast cancer. The monoclonal antibody clone 34B3, which we established, stained testicular germ cells positively. RESULTS: The rates of detection of KK-LC-1 gene and protein expression were 11.8% and 52.9%, respectively. Protein expression was detected in all triple-negative breast cancer cases studied (n=8). Furthermore, KK-LC-1 was detected in all tumours without oestrogen receptor expression. CONCLUSION: This study indicated that KK-LC-1 expression was detected in breast cancer, especially in oestrogen receptor-negative subtypes. Copyright
Authors: Robert Hsu; Yasmine Baca; Joanne Xiu; Rongfu Wang; J Nicholas Bodor; Chul Kim; Hina Khan; Hirva Mamdani; Misako Nagasaka; Sonam Puri; Stephen V Liu; W Michael Korn; Jorge J Nieva Journal: Oncotarget Date: 2021-12-07